Ferlin overview: from membrane to cancer biology

[en] In mammal myocytes, endothelial cells, and inner ear cells, ferlins are proteins involved in membrane processes such as fusion, recycling, endo- and exocytosis. They harbour several C2 domains allowing their interaction with phospholipids. Membrane biology is of extreme importance for cell survival and signalling, making Ferlin proteins core machinery indispensable for cancer cell adaptation to hostile environment. Expression of several Ferlin genes was described as altered in several cancer types. Among them myoferlin was recently discovered as highly expressed in several tumoural tissues, and negatively correlated to patient survival. Evidences suggest that myoferlin, when overexpressed, enhances cancer cell proliferation, migration and metabolism by affecting various aspects of membrane biology. Targeting myoferlin using pharmacological compounds, gene transfer technology, or interfering RNA is now considered as an emerging therapeutic strategy.

Research center :

Giga-Cancer - ULiège
d‐BRU - Dental Biomaterials Research Unit - ULiège [BE]

Disciplines :

Oncology

Author, co-author :

Peulen, Olivier ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

Rademaker, Gilles ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire

Anania, Sandy ; Université de Liège - ULiège > Cancer-Metastases Research Laboratory

Turtoi, Andrei

Bellahcene, Akeila ; Université de Liège - ULiège > Cancer-Metastases Research Laboratory

Castronovo, Vincenzo ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire

Language :

English

Title :

Ferlin overview: from membrane to cancer biology

Publication date :

August 2019

Journal title :

Cells

eISSN :

2073-4409

Publisher :

Multidisciplinary Digital Publishing Institute (MDPI), Basel, Switzerland

Special issue title :

Killing Cancer: Discovery and Selection of New Target Molecules

Volume :

Pages :

954

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

Fonds Léon Fredericq [BE]
ULiège - Université de Liège [BE]
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
FRIA - Fonds pour la Formation à la Recherche dans l'Industrie et dans l'Agriculture [BE]

Available on ORBi :

since 21 August 2019

Statistics

Number of views

105 (23 by ULiège)

Number of downloads

85 (12 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Bernardes, N.; Fialho, A.M. Perturbing the Dynamics and Organization of Cell Membrane Components: A New Paradigm for Cancer-Targeted Therapies. Int. J. Mol. Sci. 2018, 19, 3871.
Achanzar, W.E.; Ward, S. A nematode gene required for sperm vesicle fusion. J. Cell Sci. 1997, 110, 1073-1081.
Bashir, R.; Britton, S.; Strachan, T.; Keers, S.; Vafiadaki, E.; Lako, M.; Richard, I.; Marchand, S.; Bourg, N.; Argov, Z.; et al. A gene related to caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limbgirdle muscular dystrophy type 2B. Nat. Genet. 1998, 20, 37-42.
Yasunaga, S.; Grati, M.; Cohen-Salmon, M.; El-Amraoui, A.; Mustapha, M.; Salem, N.; El-Zir, E.; Loiselet, J.; Petit, C. A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness. Nat. Genet. 1999, 21, 363-369.
Davis, D.B.; Delmonte, A.J.; Ly, C.T.; McNally, E.M. Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum. Mol. Genet. 2000, 9, 217-226.
Britton, S.; Freeman, T.; Vafiadaki, E.; Keers, S.; Harrison, R.; Bushby, K.; Bashir, R. The third human FER-1-like protein is highly similar to dysferlin. Genomics 2000, 68, 313-321.
Liu, J.; Aoki, M.; Illa, I.; Wu, C.; Fardeau, M.; Angelini, C.; Serrano, C.; Urtizberea, J.A.; Hentati, F.; Hamida, M.B.; et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 1998, 20, 31-36.
Choi, B.Y.; Ahmed, Z.M.; Riazuddin, S.; Bhinder, M.A.; Shahzad, M.; Husnain, T.; Griffith, A.J.; Friedman, T.B. Identities and frequencies of mutations of the otoferlin gene (OTOF) causing DFNB9 deafness in Pakistan. Clin. Genet. 2009, 75, 237-243.
Tekin, M.; Akcayoz, D.; Incesulu, A. A novel missense mutation in a C2 domain of OTOF results in autosomal recessive auditory neuropathy. Am. J. Med. Genet. A 2005, 138, 6-10.
Doherty, K.R.; Cave, A.; Davis, D.B.; Delmonte, A.J.; Posey, A.; Earley, J.U.; Hadhazy, M.; McNally, E.M. Normal myoblast fusion requires myoferlin. Development 2005, 132, 5565-5575.
Kiselev, A.; Vaz, R.; Knyazeva, A.; Sergushichev, A.; Dmitrieva, R.; Khudiakov, A.; Jorholt, J.; Smolina, N.; Sukhareva, K.; Fomicheva, Y.; et al. Truncating variant in myof gene is associated with limb-girdle type muscular dystrophy and cardiomyopathy. Front. Genet. 2019, 10, 608.
Aoki, M.; Liu, J.; Richard, I.; Bashir, R.; Britton, S.; Keers, S.M.; Oeltjen, J.; Brown, H.E.; Marchand, S.; Bourg, N.; et al. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology 2001, 57, 271-278.
Demonbreun, A.R.; Lapidos, K.A.; Heretis, K.; Levin, S.; Dale, R.; Pytel, P.; Svensson, E.C.; McNally, E.M. Myoferlin regulation by NFAT in muscle injury, regeneration and repair. J. Cell Sci. 2010, 123, 2413-2422.
Finn, R.D.; Coggill, P.; Eberhardt, R.Y.; Eddy, S.R.; Mistry, J.; Mitchell, A.L.; Potter, S.C.; Punta, M.; Qureshi, M.; Sangrador-Vegas, A.; et al. The Pfam protein families database: Towards a more sustainable future. Nucleic Acids Res. 2016, 44, D279-D285.
Corbalan-Garcia, S.; Gómez-Fernández, J.C. Signaling through C2 domains: More than one lipid target. Biochim. Biophys. Acta 2014, 1838, 1536-1547.
Zhang, D.; Aravind, L. Identification of novel families and classification of the C2 domain superfamily elucidate the origin and evolution of membrane targeting activities in eukaryotes. Gene 2010, 469, 18-30.
Nalefski, E.A.; Falke, J.J. The C2 domain calcium-binding motif: Structural and functional diversity. Protein Sci. 1996, 5, 2375-2390.
Shin, O.-H.; Han, W.; Wang, Y.; Südhof, T.C. Evolutionarily conserved multiple C2 domain proteins with two transmembrane regions (MCTPs) and unusual Ca2+ binding properties. J. Biol. Chem. 2005, 280, 1641-1651.
Min, S.-W.; Chang, W.-P.; Südhof, T.C. E-Syts, a family of membranous Ca2+-sensor proteins with multiple C2 domains. Proc. Natl. Acad. Sci. USA 2007, 104, 3823-3828.
Rizo, J.; Sudhof, T.C. C2-domains, structure and function of a universal Ca2+-binding domain. J. Biol. Chem.1998, 273, 15879-15882.
von Poser, C.; Ichtchenko, K.; Shao, X.; Rizo, J.; Sudhof, T.C. The evolutionary pressure to inactivate. A subclass of synaptotagmins with an amino acid substitution that abolishes Ca2+ binding. J. Biol. Chem. 1997, 272, 14314-14319.
Lek, A.; Lek, M.; North, K.N.; Cooper, S.T. Phylogenetic analysis of ferlin genes reveals ancient eukaryotic origins. BMC Evol. Biol. 2010, 10, 231.
Washington, N.L.; Ward, S. FER-1 regulates Ca2+ -mediated membrane fusion during C. elegans spermatogenesis. J. Cell Sci. 2006, 119, 2552-2562.
Yan, M.; Rachubinski, D.A.; Joshi, S.; Rachubinski, R.A.; Subramani, S. Dysferlin domain-containing proteins, Pex30p and Pex31p, localized to two compartments, control the number and size of oleateinduced peroxisomes in Pichia pastoris. Mol. Biol. Cell. 2008, 19, 885-898.
Patel, P.; Harris, R.; Geddes, S.M.; Strehle, E.-M.; Watson, J.D.; Bashir, R.; Bushby, K.; Driscoll, P.C.; Keep, N.H. Solution Structure of the Inner DysF Domain of Myoferlin and Implications for Limb Girdle Muscular Dystrophy Type 2B. J. Mol. Biol. 2008, 379, 981-990.
Fuson, K.; Rice, A.; Mahling, R.; Snow, A.; Nayak, K.; Shanbhogue, P.; Meyer, A.G.; Redpath, G.M.I.; Hinderliter, A.; Cooper, S.T.; et al. Alternate splicing of dysferlin C2A confers Ca2+-dependent and Ca2+- independent binding for membrane repair. Structure 2014, 22, 104-115.
Aartsma-Rus, A.; Van Deutekom, J.C.T.; Fokkema, I.F.; Van Ommen, G.-J. B.; Den Dunnen, J.T. Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006, 34, 135-144.
Bernatchez, P.N.; Acevedo, L.; Fernandez-Hernando, C.; Murata, T.; Chalouni, C.; Kim, J.; Erdjument-Bromage, H.; Shah, V.; Gratton, J.-P.; McNally, E.M.; et al. Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. J. Biol. Chem. 2007, 282, 30745-30753.
Miyatake, Y.; Yamano, T.; Hanayama, R. Myoferlin-Mediated Lysosomal Exocytosis Regulates Cytotoxicity by Phagocytes. J. Immunol. 2018, 201, 3051-3057.
Redpath, G.M.I.; Sophocleous, R.A.; Turnbull, L.; Whitchurch, C.B.; Cooper, S.T. Ferlins Show Tissue-Specific Expression and Segregate as Plasma Membrane/Late Endosomal or Trans-Golgi/Recycling Ferlins. Traffic 2016, 17, 245-266.
Davis, D.B.; Doherty, K.R.; Delmonte, A.J.; McNally, E.M. Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J. Biol. Chem. 2002, 277, 22883-22888.
Bootman, M.D.; Rietdorf, K.; Hardy, H.; Dautova, Y.; Corps, E.; Pierro, C.; Stapleton, E.; Kang, E.; Proudfoot, D. Calcium Signalling and Regulation of Cell Function. In eLS; John Wiley & Sons, Ltd.: Chichester, UK, 2012; pp. 1-14.
Harsini, F.M.; Bui, A.A.; Rice, A.M.; Chebrolu, S.; Fuson, K.L.; Turtoi, A.; Bradberry, M.; Chapman, E.R.; Sutton, R.B. Structural Basis for the Distinct Membrane Binding Activity of the Homologous C2A Domains of Myoferlin and Dysferlin. J. Mol. Biol. 2019, 431, 2112-2126.
Therrien, C.; Fulvio, S.D.; Pickles, S.; Sinnreich, M. Characterization of lipid binding specificities of dysferlin C2 domains reveals novel interactions with phosphoinositides. Biochemistry 2009, 48, 2377-2384.
Marty, N.J.; Holman, C.L.; Abdullah, N.; Johnson, C.P. The C2 domains of otoferlin, dysferlin, and myoferlin alter the packing of lipid bilayers. Biochemistry 2013, 52, 5585-5592.
Johnson, C.P.; Chapman, E.R. Otoferlin is a calcium sensor that directly regulates SNARE-mediated membrane fusion. J. Cell Biol. 2010, 191, 187-197.
Helfmann, S.; Neumann, P.; Tittmann, K.; Moser, T.; Ficner, R.; Reisinger, E. The Crystal Structure of the C2A Domain of Otoferlin Reveals an Unconventional Top Loop Region. J. Mol. Biol. 2011, 406, 479-490.
Harsini, F.M.; Chebrolu, S.; Fuson, K.L.; White, M.A.; Rice, A.M.; Sutton, R.B. FerA is a Membrane-Associating Four-Helix Bundle Domain in the Ferlin Family of Membrane-Fusion Proteins. Sci. Rep. 2018, 8, 10949.
de Morrée, A.; Hensbergen, P.J.; van Haagen, H.H.; Dragan, I.; Deelder, A.M.; AC’t Hoen, P.; Frants, R.R.; van der Maarel, S.M. Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity. PLoS ONE 2010, 5, e13854.
Doherty, K.R.; Demonbreun, A.R.; Wallace, G.Q.; Cave, A.; Posey, A.D.; Heretis, K.; Pytel, P.; McNally, E.M. The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. J. Biol. Chem.2008, 283, 20252-20260.
Bansal, D.; Miyake, K.; Vogel, S.S.; Groh, S.; Chen, C.-C.; Williamson, R.; McNeil, P.L.; Campbell, K.P. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423, 168-172.
Lukyanenko, V.; Muriel, J.M.; Bloch, R.J. Coupling of excitation to Ca (2+) release is modulated by dysferlin. J. Physiol. 2017, 595, 5191-5207.
Lennon, N.J.; Kho, A.; Bacskai, B.J.; Perlmutter, S.L.; Hyman, B.T.; Brown, R.H. Dysferlin Interacts with Annexins A1 and A2 and Mediates Sarcolemmal Wound-healing. J. Biol. Chem. 2003, 278, 50466-50473.
Vincent, A.E.; Rosa, H.S.; Alston, C.L.; Grady, J.P.; Rygiel, K.A.; Rocha, M.C.; Barresi, R.; Taylor, R.W.; Turnbull, D.M. Dysferlin mutations and mitochondrial dysfunction. Neuromuscul. Disord. 2016, 26, 782-788.
Pramono, Z.A.D.; Lai, P.S.; Tan, C.L.; Takeda, S.; Yee, W.C. Identification and characterization of a novel human dysferlin transcript: Dysferlin_v1. Hum. Genet. 2006, 120, 410-419.
Lek, A.; Evesson, F.J.; Lemckert, F.A.; Redpath, G.M.I.; Lueders, A.-K.; Turnbull, L.; Whitchurch, C.B.; North, K.N.; Cooper, S.T. Calpains, cleaved mini-dysferlinC72, and L-type channels underpin calciumdependent muscle membrane repair. J. Neurosci. 2013, 33, 5085-5094.
Redpath, G.M.I.; Woolger, N.; Piper, A.K.; Lemckert, F.A.; Lek, A.; Greer, P.A.; North, K.N.; Cooper, S.T. Calpain cleavage within dysferlin exon 40a releases a synaptotagmin-like module for membrane repair. Mol. Biol. Cell. 2014, 25, 3037-3048.
O’Connor, V.; Lee, A.G. Synaptic vesicle fusion and synaptotagmin: 2B or not 2B? Nat. Neurosci. 2002, 5, 823-824.
Przybylski, R.J.; Szigeti, V.; Davidheiser, S.; Kirby, A.C. Calcium regulation of skeletal myogenesis. II. Extracellular and cell surface effects. Cell Calcium 1994, 15, 132-142.
Demonbreun, A.R.; Posey, A.D.; Heretis, K.; Swaggart, K.A.; Earley, J.U.; Pytel, P.; McNally, E.M. Myoferlin is required for insulin-like growth factor response and muscle growth. FASEB J. 2010, 24, 1284-1295.
Zhou, Y.; Xiong, L.; Zhang, Y.; Yu, R.; Jiang, X.; Xu, G. Quantitative proteomics identifies myoferlin as a novel regulator of A Disintegrin and Metalloproteinase 12 in HeLa cells. J. Proteom. 2016, 148, 94-104.
Galliano, M.F.; Huet, C.; Frygelius, J.; Polgren, A.; Wewer, U.M.; Engvall, E. Binding of ADAM12, a marker of skeletal muscle regeneration, to the muscle-specific actin-binding protein, α-actinin-2, is required for myoblast fusion. J. Biol. Chem. 2000, 275, 13933-13939.
Posey, A.D.; Pytel, P.; Gardikiotes, K.; Demonbreun, A.R.; Rainey, M.; George, M.; Band, H.; McNally, E.M. Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1L5) and mediate myoblast fusion. J. Biol. Chem. 2011, 286, 7379-7388.
Roux, I.; Safieddine, S.; Nouvian, R.; Grati, M.; Simmler, M.-C.; Bahloul, A.; Perfettini, I.; Le Gall, M.; Rostaing, P.; Hamard, G.; et al. Otoferlin, defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse. Cell 2006, 127, 277-289.
Chapman, E.R.; Hanson, P.I.; An, S.; Jahn, R. Ca2+ regulates the interaction between synaptotagmin and syntaxin 1. J. Biol. Chem. 1995, 270, 23667-23671.
Mohrmann, R.; de Wit, H.; Connell, E.; Pinheiro, P.S.; Leese, C.; Bruns, D.; Davletov, B.; Verhage, M.; Sørensen, J.B. Synaptotagmin interaction with SNAP-25 governs vesicle docking, priming, and fusion triggering. J. Neurosci. 2013, 33, 14417-14430.
Ramakrishnan, N.A.; Drescher, M.J.; Drescher, D.G. Direct interaction of otoferlin with syntaxin 1A, SNAP-25, and the L-type voltage-gated calcium channel Cav1.3. J. Biol. Chem. 2009, 284, 1364-1372.
Ramakrishnan, N.A.; Drescher, M.J.; Morley, B.J.; Kelley, P.M.; Drescher, D.G. Calcium regulates molecular interactions of otoferlin with soluble NSF attachment protein receptor (SNARE) proteins required for hair cell exocytosis. J. Biol. Chem. 2014, 289, 8750-8766.
Hams, N.; Padmanarayana, M.; Qiu, W.; Johnson, C.P. Otoferlin is a multivalent calcium-sensitive scaffold linking SNAREs and calcium channels. Proc. Natl. Acad. Sci. USA 2017, 114, 8023-8028.
Sharma, A.; Yu, C.; Leung, C.; Trane, A.; Lau, M.; Utokaparch, S.; Shaheen, F.; Sheibani, N.; Bernatchez, P. A new role for the muscle repair protein dysferlin in endothelial cell adhesion and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 2196-2204.
Yu, C.; Sharma, A.; Trane, A.; Utokaparch, S.; Leung, C.; Bernatchez, P. Myoferlin gene silencing decreases Tie-2 expression in vitro and angiogenesis in vivo. Vascul. Pharmacol. 2011, 55, 26-33.
Bernatchez, P.N.; Sharma, A.; Kodaman, P.; Sessa, W.C. Myoferlin is critical for endocytosis in endothelial cells. Am. J. Physiol. Cell. Physiol. 2009, 297, C484-C492.
Han, W.Q.; Xia, M.; Xu, M.; Boini, K.M.; Ritter, J.K.; Li, N.J.; Li, P.L. Lysosome fusion to the cell membrane is mediated by the dysferlin C2A domain in coronary arterial endothelial cells. J. Cell Sci. 2012, 125, 1225-1234.
Leung, C.; Shaheen, F.; Bernatchez, P.; Hackett, T.-L. Expression of myoferlin in human airway epithelium and its role in cell adhesion and zonula occludens-1 expression. PLoS ONE 2012, 7, e40478.
Stamer, W.D.; Hoffman, E.A.; Luther, J.M.; Hachey, D.L.; Schey, K.L. Protein profile of exosomes from trabecular meshwork cells. J. Proteom. 2011, 74, 796-804.
Iacobuzio-Donahue, C.A.; Maitra, A.; Shen-Ong, G.L.; van Heek, T.; Ashfaq, R.; Meyer, R.; Walter, K.; Berg, K.; Hollingsworth, M.A.; Cameron, J.L.; et al. Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression Technology. Am. J. Pathol. 2002, 160, 1239-1249.
Han, H.; Bearss, D.J.; Browne, L.W.; Calaluce, R.; Nagle, R.B.; Von Hoff, D.D. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 2002, 62, 2890-2896.
Amatschek, S.; Koenig, U.; Auer, H.; Steinlein, P.; Pacher, M.; Gruenfelder, A.; Dekan, G.; Vogl, S.; Kubista, E.; Heider, K.-H.; et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res. 2004, 64, 844-856.
Yadav, A.; Kumar, B.; Lang, J.C.; Teknos, T.N.; Kumar, P. A muscle-specific protein “myoferlin” modulates IL-6/STAT3 signaling by chaperoning activated STAT3 to nucleus. Oncogene 2017, 36, 6374-6382.
McKinney, K.Q.; Lee, Y.Y.; Choi, H.S.; Groseclose, G.; Iannitti, D.A.; Martinie, J.B.; Russo, M.W.; Lundgren, D.H.; Han, D.K.; Bonkovsky, H.L.; et al. Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. J. Proteom. 2011, 74, 79-88.
Turtoi, A.; Musmeci, D.; Wang, Y.; Dumont, B.; Somja, J.; Bevilacqua, G.; De Pauw, E.; Delvenne, P.; Castronovo, V. Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J. Proteome Res. 2011, 10, 4302-4313.
McKinney, K.Q.; Lee, J.-G.; Sindram, D.; Russo, M.W.; Han, D.K.; Bonkovsky, H.L.; Hwang, S.-I. Identification of differentially expressed proteins from primary versus metastatic pancreatic cancer cells using subcellular proteomics. Cancer Genom. Proteom. 2012, 9, 257-263.
Wang, W.S.; Liu, X.H.; Liu, L.X.; Lou, W.H.; Jin, D.Y.; Yang, P.Y.; Wang, X.L. ITRAQ-based quantitative proteomics reveals myoferlin as a novel prognostic predictor in pancreatic adenocarcinoma. J. Proteom.2013, 91, 453-465.
Adam, P.J.; Boyd, R.; Tyson, K.L.; Fletcher, G.C.; Stamps, A.; Hudson, L.; Poyser, H.R.; Redpath, N.; Griffiths, M.; Steers, G.; et al. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J. Biol. Chem. 2003, 278, 6482-6489.
Leung, C.; Yu, C.; Lin, M.I.; Tognon, C.; Bernatchez, P. Expression of myoferlin in human and murine carcinoma tumors: Role in membrane repair, cell proliferation, and tumorigenesis. Am. J. Pathol. 2013, 182, 1900-1909.
Hermanns, C.; Hampl, V.; Holzer, K.; Aigner, A.; Penkava, J.; Frank, N.; Martin, D.E.; Maier, K.C.; Waldburger, N.; Roessler, S.; et al. The novel MKL target gene myoferlin modulates expansion and senescence of hepatocellular carcinoma. Oncogene 2017, 36, 3464-3476.
Kumar, B.; Brown, N.V.; Swanson, B.J.; Schmitt, A.C.; Old, M.; Ozer, E.; Agrawal, A.; Schuller, D.E.; Teknos, T.N.; Kumar, P. High expression of myoferlin is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with HPV-status. Oncotarget 2016, 7, 18665-18677.
Song, D.H.; Ko, G.H.; Lee, J.H.; Lee, J.S.; Yang, J.W.; Kim, M.H.; An, H.J.; Kang, M.H.; Jeon, K.N.; Kim, D.C. Prognostic role of myoferlin expression in patients with clear cell renal cell carcinoma. Oncotarget 2017, 8, 89033-89039.
Koh, H.M.; An, H.J.; Ko, G.H.; Lee, J.H.; Lee, J.S.; Kim, D.C.; Seo, D.H.; Song, D.H. Identification of Myoferlin Expression for Prediction of Subsequent Primary Malignancy in Patients With Clear Cell Renal Cell Carcinoma. In Vivo 2019, 33, 1103-1108.
Kim, M.H.; Song, D.H.; Ko, G.H.; Lee, J.H.; Kim, D.C.; Yang, J.W.; Lee, H.I.; An, H.J.; Lee, J.S. Myoferlin expression and its correlation with FIGO histologic grading in early-stage endometrioid carcinoma. J. Pathol. Transl. Med. 2018, 52, 93-97.
Welton, J.L.; Khanna, S.; Giles, P.J.; Brennan, P.; Brewis, I.A.; Staffurth, J.; Mason, M.D.; Clayton, A. Proteomics analysis of bladder cancer exosomes. Mol. Cell. Proteom. 2010, 9, 1324-1338.
Mathivanan, S.; Lim, J.W.E.; Tauro, B.J.; Ji, H.; Moritz, R.L.; Simpson, R.J. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissuespecific protein signature. Mol. Cell. Proteom. 2010, 9, 197-208.
Beckler, M.D.; Higginbotham, J.N.; Franklin, J.L.; Ham, A.-J.; Halvey, P.J.; Imasuen, I.E.; Whitwell, C.; Li, M.; Liebler, D.C.; Coffey, R.J. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol. Cell. Proteom. 2013, 12, 343-355.
Ji, H.; Greening, D.W.; Barnes, T.W.; Lim, J.W.; Tauro, B.J.; Rai, A.; Xu, R.; Adda, C.; Mathivanan, S.; Zhao, W.; et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics 2013, 13, 1672-1686.
Choi, D.-S.; Choi, D.-Y.; Hong, B.S.; Jang, S.C.; Kim, D.-K.; Lee, J.; Kim, Y.-K.; Kim, K.P.; Gho, Y.S. Quantitative proteomics of extracellular vesicles derived from human primary and metastatic colorectal cancer cells. J. Extracell. Vesicles 2012, 1, 18704.
Liang, B.; Peng, P.; Chen, S.; Li, L.; Zhang, M.; Cao, D.; Yang, J.; Li, H.; Gui, T.; Li, X.; Shen, K. Characterization and proteomic analysis of ovarian cancer-derived exosomes. J. Proteom. 2013, 80, 171-182.
Sandvig, K.; Llorente, A. Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3. Mol. Cell. Proteom. 2012, 11, M111-012914.
Blomme, A.; Fahmy, K.; Peulen, O.J.; Costanza, B.; Fontaine, M.; Struman, I.; Baiwir, D.; De Pauw, E.; Thiry, M.; Bellahcène, A.; et al. Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes. Oncotarget 2016, 7, 83669-83683.
Lawrence, M.S.; Stojanov, P.; Mermel, C.H.; Robinson, J.T.; Garraway, L.A.; Golub, T.R.; Meyerson, M.; Gabriel, S.B.; Lander, E.S.; Getz, G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505, 495-501.
Anaya, J. OncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comp. Sci. 2016, 2, e67.
Tang, H.; Wei, P.; Chang, P.; Li, Y.; Yan, D.; Liu, C.; Hassan, M.; Li, D. Genetic polymorphisms associated with pancreatic cancer survival: A genome-wide association study. Int. J. Cancer 2017, 141, 678-686.
Ding, F.; Tang, H.; Nie, D.; Xia, L. Long non-coding RNA Fer-1-like family member 4 is overexpressed in human glioblastoma and regulates the tumorigenicity of glioma cells. Oncol. Lett. 2017, 14, 2379-2384.
Xia, L.; Nie, D.; Wang, G.; Sun, C.; Chen, G. FER1L4/miR-372/E2F1 works as a ceRNA system to regulate the proliferation and cell cycle of glioma cells. J. Cell. Mol. Med. 2019, 23, 3224-3233.
You, Z.; Ge, A.; Pang, D.; Zhao, Y.; Xu, S. Long noncoding RNA FER1L4 acts as an oncogenic driver in human pan-cancer. J. Cell. Physiol. 2019, 1859, 46.
Chen, Z.-X.; Chen, C.-P.; Zhang, N.; Wang, T.-X. Low-expression of lncRNA FER1L4 might be a prognostic marker in osteosarcoma. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 2310-2314.
Song, H.; Sun, W.; Ye, G.; Ding, X.; Liu, Z.; Zhang, S.; Xia, T.; Xiao, B.; Xi, Y.; Guo, J. Long non-coding RNA expression profile in human gastric cancer and its clinical significances. J. Transl. Med. 2013, 11, 225.
Kong, Y.; Ren, Z. Overexpression of LncRNA FER1L4 in endometrial carcinoma is associated with favorable survival outcome. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 8113-8118.
Eisenberg, M.C.; Kim, Y.; Li, R.; Ackerman, W.E.; Kniss, D.A.; Friedman, A. Mechanistic modeling of the effects of myoferlin on tumor cell invasion. Proc. Natl. Acad. Sci. USA 2011, 108, 20078-20083.
Li, R.; Ackerman, W.E.; Mihai, C.; Volakis, L.I.; Ghadiali, S.; Kniss, D.A. Myoferlin depletion in breast cancer cells promotes mesenchymal to epithelial shape change and stalls invasion. PLoS ONE 2012, 7, e39766.
Volakis, L.I.; Li, R.; Ackerman, W.E.; Mihai, C.; Bechel, M.; Summerfield, T.L.; Ahn, C.S.; Powell, H.M.; Zielinski, R.; Rosol, T.J.; et al. Loss of myoferlin redirects breast cancer cell motility towards collective migration. PLoS ONE 2014, 9, e86110.
Blackstone, B.N.; Li, R.; Ackerman, W.E.; Ghadiali, S.N.; Powell, H.M.; Kniss, D.A. Myoferlin depletion elevates focal adhesion kinase and paxillin phosphorylation and enhances cell-matrix adhesion in breast cancer cells. Am. J. Physiol. Cell. Physiol. 2015, 308, C642-C649.
Barnhouse, V.R.; Weist, J.L.; Shukla, V.C.; Ghadiali, S.N.; Kniss, D.A.; Leight, J.L. Myoferlin regulates epithelial cancer cell plasticity and migration through autocrine TGF-β1 signaling. Oncotarget 2018, 9, 19209-19222.
Zhang, W.; Zhou, P.; Meng, A.; Zhang, R.; Zhou, Y. Down-regulating Myoferlin inhibits the vasculogenic mimicry of melanoma via decreasing MMP-2 and inducing mesenchymal-to-epithelial transition. J. Cell. Mol. Med. 2017, 155, 739.
Turtoi, A.; Blomme, A.; Bellahcène, A.; Gilles, C.; Hennequière, V.; Peixoto, P.; Bianchi, E.; Noël, A.; De Pauw, E.; Lifrange, E.; et al. Myoferlin is a key regulator of EGFR activity in breast cancer. Cancer Res. 2013, 73, 5438-5448.
Nylandsted, J.; Becker, A.C.; Bunkenborg, J.; Andersen, J.S.; Dengjel, J.; Jäättelä, M. ErbB2-associated changes in the lysosomal proteome. Proteomics 2011, 11, 2830-2838.
Örtegren, U.; Aboulaich, N.; Öst, A.; Strålfors, P. A new role for caveolae as metabolic platforms. Trends Endocrinol. Metab. 2007, 18, 344-349.
Blomme, A.; Costanza, B.; de Tullio, P.; Thiry, M.; Van Simaeys, G.; Boutry, S.; Doumont, G.; Di Valentin, E.; Hirano, T.; Yokobori, T.; et al. Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer. Oncogene 2017, 36, 2116-2130.
Piper, A.-K.; Ross, S.E.; Redpath, G.M.; Lemckert, F.A.; Woolger, N.; Bournazos, A.; Greer, P.A.; Sutton, R.B.; Cooper, S.T. Enzymatic cleavage of myoferlin releases a dual C2-domain module linked to ERK signalling. Cell. Signal. 2017, 33, 30-40.
Fahmy, K.; Gonzalez, A.; Arafa, M.; Peixoto, P.; Bellahcène, A.; Turtoi, A.; Delvenne, P.; Thiry, M.; Castronovo, V.; Peulen, O.J. Myoferlin plays a key role in VEGFA secretion and impacts tumor-associated angiogenesis in human pancreas cancer. Int. J. Cancer 2016, 138, 652-663.
Rademaker, G.; Hennequière, V.; Brohée, L.; Nokin, M.-J.; Lovinfosse, P.; Durieux, F.; Gofflot, S.; Bellier, J.; Costanza, B.; Herfs, M.; et al. Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness. Oncogene 2018, 66, 1-15.
Rademaker, G.; Costanza, B.; Bellier, J.; Herfs, M.; Peiffer, R.; Agirman, F.; Maloujahmoum, N.; Habraken, Y.; Delvenne, P.; Bellahcène, A.; et al. Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis. Oncogenesis 2019, 8, 21.
LeBleu, V.S.; O’Connell, J.T.; Gonzalez Herrera, K.N.; Wikman, H.; Pantel, K.; Haigis, M.C.; de Carvalho, F.M.; Damascena, A.; Domingos Chinen, L.T.; Rocha, R.M.; et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 2014, 16, 992-1003.
Porporato, P.E.; Payen, V.L.; Pérez-Escuredo, J.; De Saedeleer, C.J.; Danhier, P.; Copetti, T.; Dhup, S.; Tardy, M.; Vazeille, T.; Bouzin, C.; et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 2014, 8, 754-766.
Rademaker, G.; Costanza, B.; Anania, S.; Agirman, F.; Maloujahmoum, N.; Di Valentin, E.; Goval, J.J.; Bellahcène, A.; Castronovo, V.; Peulen, O.J. Myoferlin Contributes to the Metastatic Phenotype of Pancreatic Cancer Cells by Enhancing Their Migratory Capacity through the Control of Oxidative Phosphorylation. Cancers 2019, 11, 853.
Majumder, S.; Raimondo, M.; Taylor, W.R.; Yab, T.C.; Berger, C.K.; Dukek, B.A.; Cao, X.; Foote, P.H.; Wu, C.W.; Devens, M.E.; et al.; Ahlquist, D.A. Methylated DNA in Pancreatic Juice Distinguishes Patients with Pancreatic Cancer From Controls. Clin. Gastroenterol. Hepatol. 2019. doi:10.1016/j.cgh.2019.07.017.
Song, D.H.; Ko, G.H.; Lee, J.H.; Lee, J.S.; Lee, G.-W.; Kim, H.C.; Yang, J.W.; Heo, R.W.; Roh, G.S.; Han, S.-Y.; et al. Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression. Oncol. Lett. 2016, 11, 998-1006.
Gao, X.; Wang, N.; Wu, S.; Cui, H.; An, X.; Yang, Y. Long non-coding RNA FER1L4 inhibits cell proliferation and metastasis through regulation of the PI3K/AKT signaling pathway in lung cancer cells. Mol. Med. Rep.2019, 20, 182-190.
Ma, L.; Zhang, L.; Guo, A.; Liu, L.C.; Yu, F.; Diao, N.; Xu, C.; Wang, D. Overexpression of FER1L4 promotes the apoptosis and suppresses epithelial-mesenchymal transition and stemness markers via activating PI3K/AKT signaling pathway in osteosarcoma cells. Pathol. Res. Pract. 2019, 215, 152412.
Ma, W.; Zhang, C.-Q.; Li, H.-L.; Gu, J.; Miao, G.-Y.; Cai, H.-Y.; Wang, J.-K.; Zhang, L.-J.; Song, Y.-M.; Tian, Y.-H.; et al. LncRNA FER1L4 suppressed cancer cell growth and invasion in esophageal squamous cell carcinoma. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 2638-2645.
Wang, X.; Dong, K.; Jin, Q.; Ma, Y.; Yin, S.; Wang, S. Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway. J. Cell. Biochem. 2019, 120, 6781-6788.
Liu, Z.; Shao, Y.; Tan, L.; Shi, H.; Chen, S.; Guo, J. Clinical significance of the low expression of FER1L4 in gastric cancer patients. Tumour Biol. 2014, 35, 9613-9617.
Xia, T.; Chen, S.; Jiang, Z.; Shao, Y.; Jiang, X.; Li, P.; Xiao, B.; Guo, J. Long noncoding RNA FER1L4 suppresses cancer cell growth by acting as a competing endogenous RNA and regulating PTEN expression. Sci. Rep. 2015, 5, 13445.
Xia, T.; Liao, Q.; Jiang, X.; Shao, Y.; Xiao, B.; Xi, Y.; Guo, J. Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci. Rep. 2014, 4, 6088.
Salmena, L.; Poliseno, L.; Tay, Y.; Kats, L.; Pandolfi, P.P. A ceRNA hypothesis: The rosetta stone of a hidden RNA language? Cell 2011, 146, 353-358.
Yue, B.; Sun, B.; Liu, C.; Zhao, S.; Zhang, D.; Yu, F.; Yan, D. Long non-coding RNA Fer-1-like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer. Cancer Sci. 2015, 106, 1323-1332.
Wu, J.; Huang, J.; Wang, W.; Xu, J.; Yin, M.; Cheng, N.; Yin, J. Long non-coding RNA Fer-1-like protein 4 acts as a tumor suppressor via miR-106a-5p and predicts good prognosis in hepatocellular carcinoma. Cancer Biomark. 2017, 20, 55-65.
Fei, D.; Zhang, X.; Liu, J.; Tan, L.; Xing, J.; Zhao, D.; Zhang, Y. Long Noncoding RNA FER1L4 Suppresses Tumorigenesis by Regulating the Expression of PTEN Targeting miR-18a-5p in Osteosarcoma. Cell. Physiol. Biochem. 2018, 51, 1364-1375.
Liu, S.; Zou, B.; Tian, T.; Luo, X.; Mao, B.; Zhang, X.; Lei, H. Overexpression of the lncRNA FER1L4 inhibits paclitaxel tolerance of ovarian cancer cells via the regulation of the MAPK signaling pathway. J. Cell. Biochem. 2018, 120, 7581-7589.
Théry, C. Cancer: Diagnosis by extracellular vesicles. Nature 2015, 523, 161-162.
Ciardiello, C.; Cavallini, L.; Spinelli, C.; Yang, J.; Reis-Sobreiro, M.; de Candia, P.; Minciacchi, V.R.; Di Vizio, D. Focus on Extracellular Vesicles: New Frontiers of Cell-to-Cell Communication in Cancer. Int. J. Mol. Sci.2016, 17, 175.
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
Anderson, R.G.; Ghiraldeli, L.P.; Pardee, T.S. Mitochondria in cancer metabolism, an organelle whose time has come? Biochim. Biophys. Acta Rev. Cancer 2018, 1870, 96-102.
Zhang, T.; Jingjie, L.; He, Y.; Yang, F.; Hao, Y.; Jin, W.; Wu, J.; Sun, Z.; Li, Y.; Chen, Y.; Yi, Z.; Liu, M. A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer. Nat. Commun. 2018, 9, 3726.
Li, Y.; He, Y.; Shao, T.; Pei, H.; Guo, W.; Mi, D.; Krimm, I.; Zhang, Y.; Wang, P.; Wang, X.; et al. Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin. J. Med. Chem. 2019, 62, 4949-4966.
Sondergaard, P.C.; Griffin, D.A.; Pozsgai, E.R.; Johnson, R.W.; Grose, W.E.; Heller, K.N.; Shontz, K.M.; Montgomery, C.L.; Liu, J.; Clark, K.R.; et al. AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models. Ann. Clin. Transl. Neurol. 2015, 2, 256-270.
Escobar, H.; Schöwel, V.; Spuler, S.; Marg, A.; Izsvák, Z. Full-length Dysferlin Transfer by the Hyperactive Sleeping Beauty Transposase Restores Dysferlin-deficient Muscle. Mol. Ther. Nucleic Acids 2016, 5, e277.
Potter, R.A.; Griffin, D.A.; Sondergaard, P.C.; Johnson, R.W.; Pozsgai, E.R.; Heller, K.N.; Peterson, E.L.; Lehtimäki, K.K.; Windish, H.P.; Mittal, P.J.; et al. Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy. Hum. Gene Ther. 2017, hum.2017.062.
Llanga, T.; Nagy, N.; Conatser, L.; Dial, C.; Sutton, R.B.; Hirsch, M.L. Structure-Based Designed Nano-Dysferlin Significantly Improves Dysferlinopathy in BLA/J Mice. Mol. Ther. 2017, 25, 2150-2162.
Lee, J.H.; Kim, Y.; Yoon, Y.-E.; Kim, Y.-J.; Oh, S.-G.; Jang, J.-H.; Kim, E. Development of efficient adenoassociated virus (AAV)-mediated gene delivery system with a phytoactive material for targeting human melanoma cells. New Biotechnol. 2017, 37, 194-199.
Chow, R.D.; Guzman, C.D.; Wang, G.; Schmidt, F.; Youngblood, M.W.; Ye, L.; Errami, Y.; Dong, M.B.; Martinez, M.A.; Zhang, S.; et al. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat. Neurosci. 2017, 20, 1329-1341.
Hodge, R.; Narayanavari, S.A.; Izsvák, Z.; Ivics, Z. Wide Awake and Ready to Move: 20 Years of Non-Viral Therapeutic Genome Engineering with the Sleeping Beauty Transposon System. Hum. Gene Ther. 2017, 28, 842-855.